WDNA ETF — Holdings & Analysis

The WisdomTree BioRevolution Fund (WDNA) is a sector equity ETF with $0.00B in assets under management and an expense ratio of 0.45%.

Launched in 2021, WDNA offers targeted exposure to companies expected to be significantly transformed by advancements in genetics and biotechnology. The fund employs a representative sampling strategy, investing in a selection of stocks that mirror the overall characteristics of the BioRevolution Index, while maintaining a non-diversified portfolio.

WisdomTree BioRevolution Fund (WDNA) ETF — Price, Holdings & Analysis

The WisdomTree BioRevolution Fund (WDNA) is a sector equity ETF with $0.00B in assets under management and an expense ratio of 0.45%. Launched in 2021, WDNA offers targeted exposure to companies expected to be significantly transformed by advancements in genetics and biotechnology. The fund employs a representative sampling strategy, investing in a selection of stocks that mirror the overall characteristics of the BioRevolution Index, while maintaining a non-diversified portfolio.

ETF Overview

The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the Index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.

WDNA aims to capture the growth potential of companies at the forefront of the bio-revolution, focusing on those expected to be significantly impacted by advancements in genetics and biotechnology. The fund tracks the BioRevolution Index, providing exposure to companies listed globally. WDNA utilizes a representative sampling strategy, meaning it invests in a carefully selected subset of the index's constituents that collectively mirror the risk, return, and other characteristics of the entire index. This approach allows WDNA to efficiently track the index while managing costs. The fund's top holdings include companies like Moderna Inc (4.46%), Johnson & Johnson (2.97%), and Eli Lilly and Co (2.83%). WDNA is heavily concentrated in the Healthcare sector (91.9%), with smaller allocations to Basic Materials (5.0%) and Consumer Defensive (3.1%). The fund is non-diversified, indicating a concentrated investment approach within the bio-revolution theme, making it suitable for investors seeking targeted exposure to this specific area.

Risk Metrics

WDNA's concentration in the Healthcare sector (91.9%) exposes it to sector-specific risks, meaning that the fund's performance is closely tied to the performance of the healthcare industry and any adverse events affecting this sector could significantly impact the fund's value. The fund's non-diversified status further amplifies concentration risk, as a smaller number of holdings contribute a larger portion of the fund's overall performance. As of 2026-03-15, WDNA has a beta of 1.69, indicating higher volatility compared to the broader market. The expense ratio of 0.45% will create a drag on returns, especially in periods of lower performance. their may be worth researching risk tolerance and investment horizon before investing in WDNA, given its sector concentration, non-diversified nature, and relatively high beta.

Expense Ratio

0.45%

What does WDNA hold?

Holding	Weight
Moderna Inc (MRNA)	4.46%
Johnson & Johnson (JNJ)	2.97%
Eli Lilly and Co (LLY)	2.83%
Structure Therapeutics Inc ADR (GPCR)	2.69%
Stoke Therapeutics Inc (STOK)	2.64%
Pfizer Inc (PFE)	2.50%
Natera Inc (NTRA)	2.44%
Amgen Inc (AMGN)	2.43%
BioNTech SE ADR (BNTX)	2.41%
AstraZeneca PLC (AZN.L)	2.24%

How Is the Fund Allocated?

Sector	Weight
Healthcare	91.9%
Basic Materials	5.0%
Consumer Defensive	3.1%

Country	Weight
United States	78.9%
Denmark	4.8%
United Kingdom	4.6%
Switzerland	3.9%
Germany	3.8%
Netherlands	2.0%
Japan	1.1%
Belgium	0.5%
Australia	0.3%
Other	0.1%

Dividend Yield

0.00%

First Trust NASDAQ Clean Edge Green Energy Index Fund (QCLN) — 0.56% expense ratio
WisdomTree Artificial Intelligence and Innovation Fund (WTAI) — 0.45% expense ratio
FT Energy Income Partners Enhanced Income ETF (EIPI) — 1.11% expense ratio
First Trust Indxx Global Natural Resources Income ETF (FTRI) — 0.70% expense ratio
Columbia Select Technology ETF (SEMI) — 0.75% expense ratio
Virtus Duff & Phelps Clean Energy ETF (VCLN) — 0.59% expense ratio
WisdomTree Battery Value Chain and Innovation Fund (WBAT) — 0.45% expense ratio

WisdomTree U.S. AI Enhanced Value Fund (AIVL) (US Equity) — 0.38% expense ratio
WisdomTree International MidCap Dividend Fund (DIM) (International Equity) — 0.58% expense ratio
WisdomTree Europe Hedged Equity Fund (HEDJ) (International Equity) — 0.58% expense ratio
WisdomTree International Hedged Quality Dividend Growth Fund (IHDG) (International Equity) — 0.58% expense ratio
WisdomTree U.S. High Dividend Fund (DHS) (US Equity) — 0.38% expense ratio
WisdomTree Europe Quality Dividend Growth Fund (EUDG) (International Equity) — 0.58% expense ratio

Risk Metrics

Beta: 1.69

Questions & Answers

What is WDNA and what does it track?

The WisdomTree BioRevolution Fund (WDNA) is a sector equity ETF that seeks to track the investment results of the BioRevolution Index.

This index is designed to provide exposure to equity securities of exchange-listed companies globally that are expected to be significantly transformed by advancements in genetics and biotechnology.

What is the expense ratio for WDNA?

The expense ratio for WDNA is 0.45%. This means that for every $10,000 invested in the fund, $45 is deducted annually to cover operating expenses.

While 0.45% is not extremely high, it's important to consider this cost as it will impact the overall return of the investment. When evaluating WDNA, investors should compare its expense ratio to those of similar sector equity ETFs to determine if it offers competitive value.

What are the top holdings in WDNA?

As of 2026-03-15, the top holdings in WDNA include Moderna Inc (4.46%), Johnson & Johnson (2.97%), and Eli Lilly and Co (2.83%).

These companies represent a significant portion of the fund's overall portfolio and reflect its focus on the bio-revolution theme. Other notable holdings include Structure Therapeutics Inc ADR (2.69%) and Stoke Therapeutics Inc (2.64%).

Is WDNA a good long-term investment?

Whether WDNA is a suitable long-term investment depends on an individual investor's risk tolerance, investment goals, and time horizon. WDNA offers targeted exposure to the bio-revolution theme, which may present long-term growth opportunities.

However, the fund's concentration in the Healthcare sector (91.9%) and its non-diversified nature introduce sector-specific risks.

How does WDNA compare to similar ETFs?

WDNA distinguishes itself through its specific focus on companies expected to be significantly transformed by advancements in genetics and biotechnology. While other healthcare or biotechnology ETFs may offer broader exposure, WDNA provides a more targeted approach to the 'bio-revolution' theme.

Its expense ratio is 0.45%. As of 2026-03-15, WDNA has $0.00B in assets under management.

Does WDNA pay dividends?

As of 2026-03-15, the WisdomTree BioRevolution Fund (WDNA) has a dividend yield of 0.00%. This indicates that the fund does not currently distribute dividends to its shareholders.

Investors seeking income-generating investments may want to consider other ETFs with a history of dividend payments.